Retinal Disorder Treatment Market Size, Share, Sales, Analysis, Forecast By Type (Diabetic Retinopathy, Macular Degeneration, and Others), By Dosage Form (Ointments, Gels, Eye Drops, Capsules & Tablets, and Eye Solutions), By Distribution Channel (Retail Pharmacy, Online Pharmacy, and Hospital Pharmacy), By End-user (Hospitals, Pharmacies, and Research Centers), By Geography, Industry Competition & Player Profiles, 2023-2032

The Retinal Disorder Treatment Market was worth US$ 9.6 billion in 2019 and is expected to grow at a CAGR of 7.9% through 2030. The global market is majorly driven by significant funding programs initiated by regulatory bodies intended to promote researches for ocular disorder. Moreover, rising occurrences of retinal disorders and increasing need for affordable and effective treatment solutions is likely to positively influence the market growth.

According to a data published by National Eye Institute, in America over 10 and 14 million people are estimated to suffer from diabetic retinopathy by 2030 and 2050 respectively. Similarly, as per NCBI, in Europe individuals with early and late AMD are estimated to range between 14.9 million to 21.5 million and 3.9 to 4.8 million by 2040. Furthermore, increasing aging population is also considered as one of the major driving forces for growth of global market. As per World Population Prospects: 2019 Revision, by 2050 1 in 4 and 1 in 11 European and American citizens respectively will be aged above 65 years.

Additionally, companies are focused on product innovations which is likely to positively influence the market growth. For instance, in 2017 Graybug Vision, Inc. announced that they have initiated a phase 1/ 2 trial of GB-102. The drug is used to treat wet age-related macular degeneration (AMD). As per Graybug Vision, Inc., the product is a novel intravitreal injectable depot formulation of sunitinib malate. Commercialization of novel pharmaceutical products is also expected to stimulate the market growth during the forecast period.

By geography, North America is anticipated to dominate the global market throughout the forecast period. This is mainly due to presence of leading players such as ALLERGAN PLC, Novartis AG, and Bausch & Lomb, Inc. in the region. Moreover, rising cases of retinal disorders among U.S. citizens is also likely to influence the regional growth in a positive manner. According to a study conducted by WebMD, in United States over 25 % population aged between 65 to 74 is suffering from AMD. This is expected to create growth opportunities for the global market.

Retinal Disorder Treatment Market Value Share Analysis, by Geography (2022)

The report titled “Retinal Disorder Treatment Market- Global Market Share, Trends, Analysis and Forecasts, 2023-2032”, wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global Retinal Disorder Treatment Market.

Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.

The global Retinal Disorder Treatment Market is segmented on the basis of type, dosage form, distribution channel, end-user, and geography. Based on type, the global market can be segmented into Diabetic Retinopathy, Macular Degeneration, and Others. The Macular Degeneration segment is further sub segmented into wet macular degeneration and dry macular degeneration. On the basis of dosage form, the global market can be segregated into Ointments, Gels, Eye Drops, Capsules & Tablets, and Eye solutions. By distribution channel, the global market can be divided into retail pharmacy, online pharmacy, and hospital pharmacy. Furthermore, the end-user segment can be segmented into hospitals, pharmacies, and research centers. Based on geography, the global Retinal Disorder Treatment Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Belgium, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, the UAE, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.

The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on Retinal Disorder Treatment. Further, market share of prominent companies in the global Retinal Disorder Treatment Market would also be estimated.

The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the Retinal Disorder Treatment device companies. The global Retinal Disorder Treatment Market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution.

Product portfolio would focus on all the products under the Retinal Disorder Treatment business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global Retinal Disorder Treatment Market.

Some of the prominent player involved in global Retinal Disorder Treatment Market include Bausch & Lomb, Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., F. Hoffmann-La Roche Ltd., Allergan plc, Bayer AG, Shire (Takeda Pharmaceutical Company Limited), Pfizer, Inc., Novartis AG, Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.) and Graybug Vision, Inc.

Retinal Disorder Treatment Market Segmentation:

By Type

• Diabetic Retinopathy
• Macular Degeneration
  • Wet Macular Degeneration
  • Dry Macular Degeneration
• Others

By Dosage Form

• Ointments
• Gels
• Eye Drops
• Capsules & Tablets
• Eye Solutions

By Distribution Channel

• Retail Pharmacy
• Online Pharmacy
• Hospital Pharmacy

By End-User

• Hospitals
• Pharmacies
• Research Centers

By Geography 

• North America
  • United States
  • Canada
  • Rest of North America
• Europe
  • Germany
  • United Kingdom
  • Belgium
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • India
  • China
  • Australia
  • Rest of Asia Pacific
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Rest of Middle East & Africa
• South America
  • Brazil
  • Rest of South America